PURE Bioscience Reports Fiscal 2023 Second Quarter And Six-Month Financial Results
PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2023.
- PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2023.
- Net product sales were $396,000 and $415,000 for the fiscal second quarter ended January 31, 2023 and 2022, respectively.
- Net loss for the fiscal second quarter ended January 31, 2023 was $1,060,000, compared to $702,000 for the fiscal second quarter ended January 31, 2022.
- Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2023 was $933,000, compared to $522,000 for the fiscal second quarter ended January 31, 2022.